[Form 4] CAMP4 Therapeutics Corporation Insider Trading Activity
Polaris-related investors purchased shares of Camp4 Therapeutics in a private placement on September 11, 2025. Polaris Partners VII, L.P. and Polaris Entrepreneurs' Fund VII, L.P. acquired common stock at $1.53 per share under a Securities Purchase Agreement dated September 9, 2025. Reported purchases include 1,221,721 shares and 85,468 shares respectively. After the transactions, the filing shows beneficial holdings attributed indirectly to Polaris entities totaling 2,825,500 shares, 197,661 shares, and an additional 909,090 shares held by related Polaris funds or entities. Multiple Polaris-affiliated entities and named managing members disclaim beneficial ownership except for pecuniary interests.
Gli investitori legati a Polaris hanno acquisito azioni di Camp4 Therapeutics tramite un private placement il 11 settembre 2025. Polaris Partners VII, L.P. e Polaris Entrepreneurs' Fund VII, L.P. hanno ottenuto azioni ordinarie al prezzo di 1,53$ per azione ai sensi di un Securities Purchase Agreement datato 9 settembre 2025. Le acquisizioni riportate includono 1.221.721 azioni e 85.468 azioni rispettivamente. Al termine delle operazioni, la relazione indica titoli beneficiari indirettamente attribuiti a entità Polaris per un totale di 2.825.500 azioni, 197.661 azioni e ulteriori 909.090 azioni detenute da fondi o entità Polaris correlate. Diversi enti affiliati a Polaris e membri gestori menzionati dichiarano di non detenere la titolarità benefica, se non per interessi pecuniari.
Inversores vinculados a Polaris compraron acciones de Camp4 Therapeutics en una colocación privada el 11 de septiembre de 2025. Polaris Partners VII, L.P. y Polaris Entrepreneurs' Fund VII, L.P. adquirieron acciones ordinarias a 1,53$ por acción conforme a un Securities Purchase Agreement fechado el 9 de septiembre de 2025. Las compras reportadas incluyen 1.221.721 acciones y 85.468 acciones, respectivamente. Tras las transacciones, la presentación muestra tenencias beneficiosas atribuidas indirectamente a entidades de Polaris por un total de 2.825.500 acciones, 197.661 acciones y 909.090 acciones adicionales en manos de fondos o entidades relacionadas de Polaris. Varias entidades afiliadas a Polaris y los miembros administradores mencionados declaran no poseer la titularidad beneficiosa, salvo por intereses pecuniarios.
폴라리스 계열 투자자들이 2025년 9월 11일 캠프4 Therapeutics의 비공개 배정으로 주식을 매수했습니다. Polaris Partners VII, L.P. 및 Polaris Entrepreneurs' Fund VII, L.P.가 2025년 9월 9일 자 Securities Purchase Agreement에 따라 주당 1.53달러의 조건으로 보통주를 취득했습니다. 보고된 매수 규모는 각각 1,221,721주와 85,468주입니다. 거래 후 제출 자료에는 폴라리스 계열사에 의해 간접적으로 귀속된 유익한 소유가 총 2,825,500주, 197,661주, 그리고 추가로 폴라리스 관련 펀드나 계열사 소유의 909,090주로 나타납니다. 폴라리스에 연결된 여러 계열사와 명시된 관리 구성원들은 금전적 이해관계가 있을 경우를 제외하고 유익한 소유권을 행사하지 않는다고 선언합니다.
Des investisseurs liés à Polaris ont acheté des actions de Camp4 Therapeutics lors d’un placement privé le 11 septembre 2025. Polaris Partners VII, L.P. et Polaris Entrepreneurs' Fund VII, L.P. ont acquis des actions ordinaires à 1,53$ par action dans le cadre d’un Securities Purchase Agreement daté du 9 septembre 2025. Les achats déclarés comprennent respectivement 1 221 721 et 85 468 actions. Après les transactions, le dossier indique des avoirs bénéficiaires attribués indirectement à des entités Polaris totalisant 2 825 500 actions, 197 661 actions, et 909 090 actions supplémentaires détenues par des fonds ou entités liés à Polaris. Diverses entités affiliées à Polaris et les membres gérants nommés démentent la propriété bénéficiaire, sauf pour des intérêts pécuniaires.
Polaris-bezogene Investoren haben Aktien von Camp4 Therapeutics in einer privaten Platzierung am 11. September 2025 erworben. Polaris Partners VII, L.P. und Polaris Entrepreneurs' Fund VII, L.P. erwarben Stammaktien zu 1,53$ pro Aktie gemäß einer am 9. September 2025 datierten Wertpapierkaufvereinbarung. Die gemeldeten Käufe umfassen 1.221.721 Aktien bzw. 85.468 Aktien. Nach den Transaktionen zeigt die Einreichung indirekt Polaris-Einheiten zugeschriebene wirtschaftliche Eigentümerschaften in Höhe von 2.825.500 Aktien, 197.661 Aktien und zusätzlich 909.090 Aktien, gehalten von verwandten Polaris-Fonds oder -Einheiten. Mehrere Polaris-affiliierte Einheiten und benannte geschäftsführende Mitglieder verzichten auf wirtschaftliches Eigentum, außer für vermögenswerte Interessen.
اشترى مستثمرون مرتبطون بـ Polaris أسهمًا في Camp4 Therapeutics من خلال عرض خاص في 11 سبتمبر 2025. اكتسبت Polaris Partners VII, L.P. وPolaris Entrepreneurs' Fund VII, L.P. أسهم عادية بسعر 1.53 دولار للسهم بموجب اتفاق شراء أوراق مالية مؤرّخ 9 سبتمبر 2025. تشمل المشتريات المبلغ عنها 1,221,721 سهمًا و85,468 سهمًا على التوالي. بعد المعاملات، تُظهر التوثيقات امتلاكًا مستفيدًا يُنسب بشكل غير مباشر إلى كيانات Polaris بإجمالي 2,825,500 سهم، و197,661 سهمًا، إضافة إلى 909,090 سهمًا إضافية يحتفظ بها صناديق Polaris أو كيانات مرتبطة. وتنصلت عدة كيانات مرتبطة بـ Polaris وأعضاء مديرين مذكورين من الملكية Beneficial باستثناء المصالح المالية.
与 Polaris 相关的投资者在 2025 年 9 月 11 日通过私人配售购买了 Camp4 Therapeutics 的股份。Polaris Partners VII, L.P. 与 Polaris Entrepreneurs' Fund VII, L.P. 根据日期为 2025 年 9 月 9 日的证券购买协议,以每股 1.53 美元的价格取得普通股。披露的购买分别为 1,221,721 股和 85,468 股。交易完成后,该申报显示间接归属于 Polaris 实体的受益所有权合计为 2,825,500 股、197,661 股,以及再加上由相关 Polaris 基金或实体持有的 909,090 股。多家与 Polaris 相关的实体及被点名的管理成员声明不享有受益所有权,除非出于金钱利益。
- Material participation in a private placement by Polaris funds at $1.53 per share demonstrates continued investor support
- Significant aggregate holdings reported (including 1,221,721 shares acquired) which could strengthen investor alignment and access to follow-on financing
- None.
Insights
TL;DR: Significant private-placement purchases by Polaris funds increase their stake at $1.53, signaling committed investor support.
The filing documents a private placement where affiliated Polaris funds acquired Camp4 common stock at $1.53 per share. The largest reported acquisition was 1,221,721 shares, with additional smaller allocations. Combined reported holdings assigned to Polaris-related entities and partnerships represent material single-entity positions that could influence governance or future financing dynamics. The repeated disclaimer language is standard for fund structures but confirms voting and dispositive power may be shared among managing members. For investors, the transaction is a clear indicator of continued backing from a strategic venture investor.
TL;DR: Disclosure shows layered ownership and standard disclaimer language; potential shared control but no explicit transfer of director status.
The Form 4 lists multiple Polaris entities and named managing members with indirect ownership and customary disclaimers. The report clarifies which vehicles directly hold the shares and identifies the management entities that may have shared voting, investment, and dispositive power. While the filing does not state any change in board composition, the scale of holdings could affect future governance votes. The multiple signatures by counsel and attorneys-in-fact reflect centralized execution rather than individual transactions.
Gli investitori legati a Polaris hanno acquisito azioni di Camp4 Therapeutics tramite un private placement il 11 settembre 2025. Polaris Partners VII, L.P. e Polaris Entrepreneurs' Fund VII, L.P. hanno ottenuto azioni ordinarie al prezzo di 1,53$ per azione ai sensi di un Securities Purchase Agreement datato 9 settembre 2025. Le acquisizioni riportate includono 1.221.721 azioni e 85.468 azioni rispettivamente. Al termine delle operazioni, la relazione indica titoli beneficiari indirettamente attribuiti a entità Polaris per un totale di 2.825.500 azioni, 197.661 azioni e ulteriori 909.090 azioni detenute da fondi o entità Polaris correlate. Diversi enti affiliati a Polaris e membri gestori menzionati dichiarano di non detenere la titolarità benefica, se non per interessi pecuniari.
Inversores vinculados a Polaris compraron acciones de Camp4 Therapeutics en una colocación privada el 11 de septiembre de 2025. Polaris Partners VII, L.P. y Polaris Entrepreneurs' Fund VII, L.P. adquirieron acciones ordinarias a 1,53$ por acción conforme a un Securities Purchase Agreement fechado el 9 de septiembre de 2025. Las compras reportadas incluyen 1.221.721 acciones y 85.468 acciones, respectivamente. Tras las transacciones, la presentación muestra tenencias beneficiosas atribuidas indirectamente a entidades de Polaris por un total de 2.825.500 acciones, 197.661 acciones y 909.090 acciones adicionales en manos de fondos o entidades relacionadas de Polaris. Varias entidades afiliadas a Polaris y los miembros administradores mencionados declaran no poseer la titularidad beneficiosa, salvo por intereses pecuniarios.
폴라리스 계열 투자자들이 2025년 9월 11일 캠프4 Therapeutics의 비공개 배정으로 주식을 매수했습니다. Polaris Partners VII, L.P. 및 Polaris Entrepreneurs' Fund VII, L.P.가 2025년 9월 9일 자 Securities Purchase Agreement에 따라 주당 1.53달러의 조건으로 보통주를 취득했습니다. 보고된 매수 규모는 각각 1,221,721주와 85,468주입니다. 거래 후 제출 자료에는 폴라리스 계열사에 의해 간접적으로 귀속된 유익한 소유가 총 2,825,500주, 197,661주, 그리고 추가로 폴라리스 관련 펀드나 계열사 소유의 909,090주로 나타납니다. 폴라리스에 연결된 여러 계열사와 명시된 관리 구성원들은 금전적 이해관계가 있을 경우를 제외하고 유익한 소유권을 행사하지 않는다고 선언합니다.
Des investisseurs liés à Polaris ont acheté des actions de Camp4 Therapeutics lors d’un placement privé le 11 septembre 2025. Polaris Partners VII, L.P. et Polaris Entrepreneurs' Fund VII, L.P. ont acquis des actions ordinaires à 1,53$ par action dans le cadre d’un Securities Purchase Agreement daté du 9 septembre 2025. Les achats déclarés comprennent respectivement 1 221 721 et 85 468 actions. Après les transactions, le dossier indique des avoirs bénéficiaires attribués indirectement à des entités Polaris totalisant 2 825 500 actions, 197 661 actions, et 909 090 actions supplémentaires détenues par des fonds ou entités liés à Polaris. Diverses entités affiliées à Polaris et les membres gérants nommés démentent la propriété bénéficiaire, sauf pour des intérêts pécuniaires.
Polaris-bezogene Investoren haben Aktien von Camp4 Therapeutics in einer privaten Platzierung am 11. September 2025 erworben. Polaris Partners VII, L.P. und Polaris Entrepreneurs' Fund VII, L.P. erwarben Stammaktien zu 1,53$ pro Aktie gemäß einer am 9. September 2025 datierten Wertpapierkaufvereinbarung. Die gemeldeten Käufe umfassen 1.221.721 Aktien bzw. 85.468 Aktien. Nach den Transaktionen zeigt die Einreichung indirekt Polaris-Einheiten zugeschriebene wirtschaftliche Eigentümerschaften in Höhe von 2.825.500 Aktien, 197.661 Aktien und zusätzlich 909.090 Aktien, gehalten von verwandten Polaris-Fonds oder -Einheiten. Mehrere Polaris-affiliierte Einheiten und benannte geschäftsführende Mitglieder verzichten auf wirtschaftliches Eigentum, außer für vermögenswerte Interessen.